Exelixis, Ipsen report additional Phase II data for cabozantinib in untreated RCC

In September, Exelixis Inc. (NASDAQ:EXEL) and partner Ipsen Group (Euronext:IPN; Pink:IPSEY) reported additional data from the open-label Phase II CABOSUN trial in 157 patients with previously untreated advanced renal cell carcinoma (RCC) showing that first-line treatment with once-daily 60 mg oral

Read the full 416 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE